Skip to main content

Articles

Page 140 of 142

  1. Hypertension and diabetes mellitus are closely interrelated and coexist in as many as two-thirds of patients with type 2 diabetes. The consequent risk of such an association is an accelerated development of at...

    Authors: Cornel Pater, Deepak Bhatnagar, Jean-Pascal Berrou, Joachim Luszick and Katrin Beckmann

    Citation: Current Controlled Trials in Cardiovascular Medicine 2004 5:9

    Content type: Research

    Published on:

  2. A large number of randomized clinical trials with important health outcomes are completed each year. Those with favorable findings are typically reported and published rapidly, while the publication of those w...

    Authors: Curt D Furberg, Mark A Hall and Mary Ann Sevick

    Citation: Current Controlled Trials in Cardiovascular Medicine 2004 5:6

    Content type: Commentary

    Published on:

  3. Noncompliance with study medications is an important issue in the design of endpoint clinical trials. Including noncompliant patient data in an intention-to-treat analysis could seriously decrease study power....

    Authors: Steven M Snapinn, Qi Jiang and Boris Iglewicz

    Citation: Current Controlled Trials in Cardiovascular Medicine 2004 5:5

    Content type: Review

    Published on:

  4. The existence of effective therapies for most cardiovascular disease states, coupled with increased requirements that potential benefits of new drugs be evaluated on clinical rather than surrogate endpoints, m...

    Authors: Cornel Pater

    Citation: Current Controlled Trials in Cardiovascular Medicine 2004 5:4

    Content type: Review

    Published on:

  5. Ximelagatran is a novel oral direct thrombin inhibitor. It has favorable pharmacodynamic properties, with a broad therapeutic range without the need for anticoagulation monitoring. We aimed to discover whether...

    Authors: Christopher J Boos and Ranjit S More

    Citation: Current Controlled Trials in Cardiovascular Medicine 2004 5:3

    Content type: Review

    Published on:

  6. Trials in the 1990s demonstrated that medical therapy is as effective as invasive therapies for treating single-vessel coronary disease. Yet more recent studies enrolling patients with this condition have focu...

    Authors: Samer Jabbour, Shmuel Ravid and Bernard Lown

    Citation: Current Controlled Trials in Cardiovascular Medicine 2004 5:2

    Content type: Review

    Published on:

  7. In order to avoid the complications associated with thromboembolic disease, patients with this condition typically are placed on long-term anticoagulant therapy. This report compares bleeding complications in ...

    Authors: Ufuk Yetkin, Özalp Karabay and Hakan Önol

    Citation: Current Controlled Trials in Cardiovascular Medicine 2004 5:1

    Content type: Research

    Published on:

  8. A large body of data derived from animal, epidemiological and clinical studies indicate that n-3 polyunsaturated fatty acids have a favourable effect on the prognosis of patients with cardiovascular disease in...

    Authors: Cornel Pater, Daniele Compagnone, Joachim Luszick and Cees-Nico Verboom

    Citation: Current Controlled Trials in Cardiovascular Medicine 2003 4:2

    Content type: Research

    Published on:

  9. Currently, there are a lack of investigations that have examined the effect of participating in a comprehensive cardiac rehabilitation program on quality of life and physiological measures in women of differen...

    Authors: Michael D Kennedy, Mark Haykowsky, Bill Daub, Karen van Lohuizen, Grant Knapik and Bill Black

    Citation: Current Controlled Trials in Cardiovascular Medicine 2003 4:1

    Content type: Research

    Published on:

  10. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is a randomized, double-blind, active-controlled trial designed to compare the rate of coronary heart disease events in ...

    Authors: Linda B Piller, Barry R Davis, Jeffrey A Cutler, William C Cushman, Jackson T Wright Jr, Jeff D Williamson, Frans HH Leenen, Paula T Einhorn, Otelio S Randall, John S Golden and L Julian Haywood

    Citation: Current Controlled Trials in Cardiovascular Medicine 2002 3:10

    Content type: Research

    Published on:

  11. Cardiac rehabilitation programs (CRP) represent comprehensive interventions that are typically limited to four months. Following completion of CRP, it appears that risk factors and lifestyle behaviours may det...

    Authors: Scott A Lear, Andrew Ignaszewski, Wolfgang Linden, Anka Brozic, Marla Kiess, John J Spinelli, P Haydn Pritchard and Jiri J Frohlich

    Citation: Current Controlled Trials in Cardiovascular Medicine 2002 3:9

    Content type: Research

    Published on:

  12. PROSPER was designed to investigate the benefits of treatment with pravastatin in elderly patients for whom a typical doctor might consider the prescription of statin therapy to be a realistic option.

    Authors: Ian Ford, Gerard Jan Blauw, Michael B Murphy, James Shepherd, Stuart M Cobbe, Edward LEM Bollen, Brendan M Buckley, J Wouter Jukema, Michael Hyland, Allan Gaw, A Margot Lagaay, Ivan J Perry, Peter Macfarlane, John Norrie, A Edo Meinders, Brian J Sweeney…

    Citation: Current Controlled Trials in Cardiovascular Medicine 2002 3:8

    Content type: Research

    Published on:

  13. The "integrated safety report" of the drug registration files submitted to health authorities usually summarizes the rates of adverse events observed for a new drug, placebo or active control drugs by pooling ...

    Authors: Michel Lièvre, Michel Cucherat and Alain Leizorovicz

    Citation: Current Controlled Trials in Cardiovascular Medicine 2002 3:6

    Content type: Commentary

    Published on:

  14. Antioxidant supplementation with vitamin E had no effect in the prevention of cardiovascular diseases (CVD) in three recent large, randomized clinical trials. In order to reassess critically the role of vitami...

    Authors: Chiara Chiabrando, Fausto Avanzini, Claudia Rivalta, Fabio Colombo, Roberto Fanelli, Gaetana Palumbo and Maria Carla Roncaglioni

    Citation: Current Controlled Trials in Cardiovascular Medicine 2002 3:5

    Content type: Research

    Published on:

  15. The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study was the first trial to assess whether statins might be of clinical benefit in those with recently unstable coronary disease. M...

    Authors: Herbert D Aronow

    Citation: Current Controlled Trials in Cardiovascular Medicine 2002 3:3

    Content type: Commentary

    Published on:

  16. Although diabetes mellitus is predominantly a metabolic disorder, recent data suggest that it is as much a vascular disorder. Cardiovascular complications are the leading cause of death and disability in patie...

    Authors: Prakash C Deedwania

    Citation: Current Controlled Trials in Cardiovascular Medicine 2002 3:2

    Content type: Review

    Published on:

  17. Overweight older adults are often counseled to lose weight, even though there is little evidence of excess mortality in that age group. Overweight and underweight may be more associated with health status than...

    Authors: Paula Diehr, Anne B Newman, Sharon A Jackson, Lewis Kuller and Neil Powe

    Citation: Current Controlled Trials in Cardiovascular Medicine 2002 3:1

    Content type: Research

    Published on:

  18. The treatment of patients with coronary artery disease continues to evolve; all three strategies – medical therapy, surgical revascularization, and percutaneous coronary intervention – have changed. Medical th...

    Authors: David R Holmes Jr

    Citation: Trials 2001 2:263

    Content type: Commentary

    Published on:

  19. This commentary has two purposes: to summarize the rationale, design and initial results of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) trial; and to provide a hist...

    Authors: Lawrence R Krakoff

    Citation: Trials 2001 2:254

    Content type: Commentary

    Published on:

  20. The identification of angiogenic growth factors, such as vascular endothelial growth factor and fibroblast growth factor, has fueled interest in using such factors to induce therapeutic angiogenesis. The resul...

    Authors: Yin-Shan Ng and Patricia A D'Amore

    Citation: Trials 2001 2:278

    Content type: Review

    Published on:

Annual Journal Metrics